Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)

December 15, 2023

Contacts

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of MEI Pharma, Inc. (Nasdaq:MEIP) concerning the Company and its directors’ and officers’ possible violations of state laws.

If you own MEI Pharma stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Tom Kennedy, of GPM, 230 Park Avenue, Suite 358, New York, NY 10169 at tkennedy@glancylaw.com, or at 212-682-5340. If you inquire by email please include your mailing address, telephone number, and the number of shares purchased and held.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Related news for (MEIP)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.